Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epinephrine intranasal spray - ARS Pharmaceuticals

Next Previous
Drug Profile

Epinephrine intranasal spray - ARS Pharmaceuticals

Alternative Names: Adrenaline nasal spray - ARS Pharmaceuticals; ARS 1; ARS-2; EURneffy; neffy; Neffy™

Latest Information Update: 02 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARS Pharmaceuticals
  • Developer Alfresa Pharma Corporation; ALK-Abello; ARS Pharmaceuticals
  • Class Anti-infectives; Antiallergics; Antiasthmatics; Bronchodilators; Catecholamines; Ethanolamines; Skin disorder therapies; Small molecules
  • Mechanism of Action Alpha adrenergic receptor agonists; Beta adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaphylaxis
  • Phase II Asthma; Urticaria
  • Phase I Allergic rhinitis
  • No development reported Respiratory tract infections

Most Recent Events

  • 26 Jun 2025 Launched for Anaphylaxis (In adolescents, In children, In adults) in Germany (Intranasal)
  • 25 Jun 2025 ALK submits sNDA for 1 mg Epinephrine nasal spray for Anaphylaxis to European Medicines Agency
  • 14 May 2025 ARS Pharmaceuticals plans to launch Epinephrine intranasal spray (EURneffy®) for Anaphylaxis in Germany, in mid-2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top